Form 4: Entero Therapeutics CFO Sells Shares to Cover Tax Obligations

Sarah Romano, CFO of Entero Therapeutics, sold 621 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Summary

• On July 2, 2024, Sarah Romano, the Chief Financial Officer of Entero Therapeutics, Inc., sold 621 shares of the company's common stock.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.07, with individual transactions ranging from $1.05 to $1.16.
• Following the transaction, Romano still beneficially owns 18,490 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: Neutral sentiment as the transaction is a routine sale to cover tax obligations and doesn't indicate a change in the executive's confidence in the company.

Industry Context

This type of transaction, where executives sell shares to cover tax obligations related to vesting equity, is a common practice.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.

Key Dates

Keywords

Entero Therapeutics, Sarah Romano, CFO, stock sale, Form 4, RSU, tax withholding, ENTO